EUCTR2015-005642-59-DK进行中（未招募）1 期
Phase II trial: uPAR-PET for prognostication in patients with non-small cell lung cancer, malignant pleural mesothelioma and large cell neuroendocrine carcinoma of the lung
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET0 个研究点开始时间: 2016年1月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically verified NSCLC
- •- Stage IV disease
- •- Operable disease
- •- Age above 18
- •- The participants must be capable of understanding and giving full informed written consent
- •- Histologically verified MPM
- •- Age above 18
- •- The participants must be capable of understanding and giving full informed written consent
- •- Histologically verified LCNEC
- •- Age above 18
- •- The participants must be capable of understanding and giving full informed written consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Study I, II, III:
- •- Pregnancy
- •- Lactation/breast feeding
- •- Age above 85 years
- •- Weight above 140 kg
- •- Treatment with neoadjuvant chemotherapy
- •- Allergy to 68Ga-NOTA-AE105
研究者
相似试验
进行中（未招募）
1 期
uPAR-PET/CT for prognostication in head- and neck cancerHead and neck cancerMedDRA version: 19.0Level: HLTClassification code 10026660Term: Malignant oral cavity neoplasmsSystem Organ Class: 100000004856MedDRA version: 19.0Level: HLTClassification code 10028801Term: Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecifiedSystem Organ Class: 100000004864MedDRA version: 19.0Level: HLTClassification code 10023826Term: Laryngeal neoplasms malignantSystem Organ Class: 100000004864EUCTR2016-002082-65-DKAndreas Kjaer
进行中（未招募）
1 期
uPAR-PET - a new method for determining lymph node metastases in breast cancer patientsMedDRA version: 18.1Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 100000004864breast cancerEUCTR2015-004503-23-DKRigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET
进行中（未招募）
1 期
uPAR-PET/MRI in patients with prostate cancer for evaluation of tumor aggressivenessProstate cancerEUCTR2017-002276-37-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET52
进行中（未招募）
1 期
uPAR PET/CT og FDG PET/CT til præoperativ stadieinddeling af patienter med nydiagnosticeret Gynækologisk Kræftgynecological cancers:Vulvar cancerendometrial cancer (uterine cancer)cervical cancerovarian cancerMedDRA version: 20.0Level: LLTClassification code 10007107Term: Cancer of ovarySystem Organ Class: 100000021045MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000020935MedDRA version: 20.0Level: LLTClassification code 10047743Term: Vulval cancer NOSSystem Organ Class: 100000021101MedDRA version: 20.0Level: LLTClassification code 10007063Term: Cancer of endometriumSystem Organ Class: 100000021008MedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000020977EUCTR2016-004638-99-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET350
进行中（未招募）
1 期
Phase II trial: uPAR PET/CT and FDG PET/MRI for determining lymph node metastases in patients with bladder cancerrinary bladder cancerMedDRA version: 19.0Level: LLTClassification code 10005004Term: Bladder cancer NOSSystem Organ Class: 100000004864EUCTR2016-001026-33-DKRigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET40